Making a meaningful difference

Turning scientific innovation into meaningful impact

Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing novel, multifunctional biotherapeutics for difficult-to-treat diseases. Through our proprietary platforms, scientific expertise and global partnerships, we aim to improve the standard of care for patients.

Partner with us

Integrating partnerships and collaborations is core to our business strategy and allows us to accelerate our efforts to bring novel therapeutics to the broadest group of patients.

News

November 4, 2026

Zymeworks to Present Preclinical Data on ZW1953, a Multispecific T Cell Engager with Integrated CD28 Co-stimulation for Acute Myeloid Leukemia, at ASH 2026

October 23, 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

October 23, 2026

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3